Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•10/11/2026•07:30 ET
0
Key Highlights
- ➤$59.1M Q3 net income versus $7.7M loss year-over-year
- ➤$337.5M cash, equivalents and marketable securities at September 30
- ➤$230M tender offer repurchased 46M shares at $5.00 each
- ➤Japan lawsuits expand LNP patent enforcement against Pfizer/BioNTech
- ➤FDA lifted AB-101 clinical hold, enabling additional U.S. development
Expert Statements
Lindsay Androski, President and CEO of Arbutus Biopharma
“This has been a busy and productive quarter for the Arbutus team”
Lindsay Androski, President and CEO of Arbutus Biopharma
“I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”
Lindsay Androski, President and CEO of Arbutus Biopharma
“We look forward to continuing this momentum in Q4 and beyond.”
Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant
Successfully returned $230M of capital to shareholders via tender offer in early October 2026
Get started
Create a free account to read the full story.